Actualités

Just over a month since its initial public offering, SpaceX has delivered one of the weakest post-debut performances of any major U.S. listing since the end of the 2008-2009 financial crisis. A Barron’s analysis found that the stock performed worse than 90% of other U.S. IPOs with market capitalizations of $1 billion or more since July, 2009. Over the first 27 trading days, SpaceX was down 23% from its first day closing price of $161.

JNJ's Innovative Medicine unit posts strong Q2 growth despite Stelara's patent loss. See what's fueling momentum into H2 2026.

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HDV quietly stacks a 3.1% income stream on top of equity gains that have left the S&P 500 in the dust this year, but the fund's concentrated sector bets carry a catch that most yield-seekers overlook.

If you're looking for more frequent payouts, you can still enjoy the benefits of low fees and broad diversification, thanks to these top monthly dividend ETFs.

When quality goes on sale, it's time to back up the truck.

Drugmakers have announced 37 biotech acquisitions worth at least $1 billion this year, topping the previous annual record.

ABBV's Q2 oncology revenues may edge lower as Imbruvica weakness outweighs gains from Venclexta and newer cancer therapies.

A pharmaceutical giant is on an incredible run fueled by blockbuster drugs, forcing investors to ask if the price of admission already accounts for the entire victory lap.

In July 2026, Allergan Aesthetics, an AbbVie company, received European Commission approval for Boey (trenibotulinumtoxinE), a rapid-onset, short-duration botulinum neurotoxin serotype E for adults with psychologically impactful moderate to severe glabellar lines, following similar approval in Canada. As the first approved serotype E neurotoxin in Europe with effects beginning as early as eight hours and lasting about two to three weeks, Boey broadens AbbVie’s aesthetics portfolio with a...

It looks like a great buy-and-hold option.

AbbVie (ABBV) closed at $256.18 in the latest trading session, marking a +1.11% move from the prior day.

Management lifted its profit outlook, and investors have more than quadrupled that bet. The question now is what they're really paying for.

This pharma giant is grabbing headlines, but its real value for your portfolio lies in how it moves on the market's worst days.

Strong biotech returns, major pharma acquisitions and new IPO filings are reshaping the 2026 U.S. listing market.

(Bloomberg) -- The biotechnology sector is stealing the US IPO market thunder from artificial intelligence-related listings, delivering standout returns as bankers line up a steady stream of summer debuts.Most Read from BloombergYemen’s Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshot’s Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshot’s Kimi K3 May Be More About Memory Than ComputeUS Strikes Iran in Escalating Cam

Billionaire investors such as Peter Thiel and Christian Angermayer are believers in the benefits of using psychedelics derived from magic mushrooms...

The healthcare giant's pharma division is booming, but analysts on its latest call wanted to know if that's enough to cover for a sudden slowdown in MedTech.

Management lifted its profit outlook, and investors have more than quadrupled that bet. The question now is what they're really paying for.

For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies. Bispecific antibodies are being tested by Bristol Myers Squibb (with its partner BioNTech ), AstraZeneca and the biotech firm Summit Therapeutics ADCs have already rung up big sales for Astra, Pfizer Gilead Sciences and Roche Holding but Merck has a strong contender in development.

There's no need to panic.

They can help stabilize your portfolio in these otherwise volatile times.

All three pharma giants have left the S&P 500 in the dust, but surging returns and strong fundamentals tell very different stories about where each stock goes from here.

The drugmaker looks expensive today, but the real story is what you are actually paying for the earnings of tomorrow.

Allergan Aesthetics, an AbbVie company (NYSE:ABBV), received European Commission approval for Boey (trenibotulinumtoxinE). Boey is described as the first rapid onset, short duration neurotoxin for the treatment of frown lines available in Europe. This approval gives AbbVie a differentiated addition to its aesthetics portfolio in Europe, an area where the company already has an established presence. By targeting frown lines with a rapid onset profile and shorter treatment duration, Boey is...

With 10-year Treasuries near 4.62%, VYM's $94.6 billion portfolio faces a real test from risk-free yields, and two familiar names inside the fund are quietly raising red flags about future income growth.

Citi analysts laid out the appeal of biopharma stocks, with the NYSE Arca Pharmaceutical Index outrunning the S&P in the last month.

ABBV's neuroscience business is expected to post solid Q2 growth, with key brands and Vyalev in focus ahead of earnings on July 31.

Abbott Laboratories (NYSE:ABT) reported second-quarter 2026 comparable sales growth of 4.8% and adjusted earnings per share of $1.31, with Chairman and Chief Executive Officer Robert Ford saying results marked an acceleration from the prior two quarters. The company reaffirmed its full-year compara

While the market focuses on a single class of blockbuster drugs, a different story is unfolding inside the company. Lilly’s immunology, oncology, and neuroscience medicines are quietly compounding at a blistering pace. These other therapeutic areas collectively grew by 160% last quarter, a rate that suggests a much broader growth engine is taking shape.